All 1 tracked stories fall under one category: fda-approval. Society of Family Planning is most often covered alongside 5th U.S. Circuit Court of Appeals, which appears in 1 of these 1 story. Society of Family Planning appears in 1 tracked Biotech story from September 9, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Society of Family Planning
All 1 tracked stories fall under one category: fda-approval. Society of Family Planning is most often covered alongside 5th U.S. Circuit Court of Appeals, which appears in 1 of these 1 story. Society of Family Planning appears in 1 tracked Biotech story from September 9, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 5 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Society of Family Planning. Shared-story counts are live from our verified record — not editorial picks.
The biopharmaceutical sector is watching the 5th Circuit review of mifepristone's FDA prescribing rules. At least 60% of U.S. abortions use the two-drug regimen, making the drug's distribution and label conditions a high-stakes regulatory precedent.